In his presentation "How to use CRISPR-Cas to combat AMR" at the ESCMID ... researchers started to search for alternative methods to fight MDR infections rather than going through the process ...

Several companies are using CRISPR to edit human genomes in an attempt to treat (and even cure) genetic diseases. Their therapies either use an ex vivo approach or an in vivo approach. With ex ...

Base and Prime Editing Offer Precision CRISPR-based systems that rely on traditional Cas nucleases like Cas9 cut through both strands of DNA which can lead to undesirable and even dangerous edits to ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.